List of Excipients in Branded Drug NAPROXEN SODIUM HEADACHE PAIN

Generic Drugs Containing NAPROXEN SODIUM HEADACHE PAIN

Company	Ingredient	NDC	Excipient
Aurohealth LLC	naproxen sodium	58602-737	FD&C BLUE NO. 2--ALUMINUM LAKE
Aurohealth LLC	naproxen sodium	58602-737	HYPROMELLOSE 2910
Aurohealth LLC	naproxen sodium	58602-737	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in NAPROXEN SODIUM HEADACHE PAIN?

# Of NDCs	Excipient
1	FD&C BLUE NO. 2--ALUMINUM LAKE
1	HYPROMELLOSE 2910
1	MAGNESIUM STEARATE

Naproxen Sodium Headache Pain: Excipient Strategy, Patent Position and Commercial Opportunities

Last updated: September 24, 2026

Naproxen sodium 220 mg is a mature, over-the-counter NSAID used for temporary relief of minor aches and pains, including headache. The active ingredient has no meaningful remaining composition-of-matter exclusivity in the United States. Commercial value therefore depends on dosage-form performance, excipient differentiation, brand positioning, retailer access, manufacturing cost and regulatory execution.

The strongest opportunities are fast-disintegrating tablets, easy-swallow dosage forms, lower-irritation presentations, migraine-oriented combinations, liquid or powder formats, and private-label products with optimized cost and packaging. Excipient changes alone are unlikely to create durable patent protection unless they produce measurable improvements in stability, dissolution, tolerability, manufacturability or patient adherence.

What is naproxen sodium used for in headache pain?

Naproxen sodium is the sodium salt of naproxen, a nonsteroidal anti-inflammatory drug. In the United States, OTC naproxen sodium products generally contain 220 mg per tablet, equivalent to 200 mg of naproxen, and are labeled for temporary relief of minor aches and pains, including headache, toothache, muscular aches, backache and menstrual cramps.[1]

Product attribute	Typical OTC position
Active ingredient	Naproxen sodium
Common strength	220 mg
Naproxen equivalent	200 mg
Dosage form	Immediate-release tablet or caplet
Main consumer claim	Temporary relief of minor aches and pains
Typical adult dosing	1 tablet every 8 to 12 hours
OTC age positioning	Adults and children 12 years and older, subject to label directions
Drug class	NSAID
Key risks	Gastrointestinal bleeding, ulceration, cardiovascular events, renal effects and hypersensitivity
Sodium content	Approximately 20 mg per 220 mg dose, calculated from molecular composition

The sodium salt is more water-soluble than naproxen acid and is used to support dissolution and onset in oral immediate-release products. It does not eliminate the class risks associated with NSAIDs.

What excipients are used in naproxen sodium headache tablets?

Commercial formulations typically use excipients for tablet binding, disintegration, lubrication, flow control, coating, color and stability. Exact compositions differ by manufacturer and product and should be confirmed against the applicable product label, DailyMed record or regulatory filing.

Core excipient functions

Formulation function	Common excipient classes	Commercial purpose
Diluent	Microcrystalline cellulose, lactose, starch, dibasic calcium phosphate	Controls tablet size, density and compression
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet strength
Disintegrant	Croscarmellose sodium, sodium starch glycolate, crospovidone	Promotes rapid tablet breakup
Glidant	Colloidal silicon dioxide	Improves powder flow
Lubricant	Magnesium stearate, stearic acid	Reduces ejection force and tooling adhesion
Film coating	Hypromellose, polyethylene glycol, titanium dioxide, iron oxides	Supports swallowability, appearance and identification
Sweetener or flavor	Sucralose, saccharin, flavor systems	Used in chewable, powder or liquid formats
Suspending agent	Cellulose derivatives, xanthan gum, carbomers	Maintains uniformity in liquid products
Preservative	Product-specific antimicrobial systems	Supports multidose liquid stability

The principal excipient design constraint is balancing rapid disintegration against tablet robustness. Excessive lubricant, high compression force or hydrophobic coating can delay wetting and dissolution. A formulation intended to support a rapid-onset consumer claim must demonstrate consistent dissolution after scale-up and long-term storage.

Which excipient strategies can improve naproxen sodium performance?

Fast-disintegrating tablet strategy

A fast-disintegrating tablet can combine low-to-moderate compression force with a high-performance superdisintegrant. Crospovidone, croscarmellose sodium and sodium starch glycolate are established options, but the best choice depends on granulation method, particle-size distribution, lubricant level and target dissolution profile.

A commercial formulation program should evaluate:

• Disintegration time across tablet hardness ranges.
• Dissolution in relevant media.
• Sensitivity to humidity.
• Friability and mechanical strength.
• Lubrication impact.
• Stability of the sodium salt.
• Tablet weight and packaging requirements.

The opportunity is strongest when the product can deliver consistent early dissolution without sacrificing shelf life or transportation durability.

Easy-swallow caplet strategy

Large or rough tablets are a barrier for headache products because consumers may already experience nausea or sensitivity. A smooth film-coated caplet can improve swallowability without changing the active ingredient.

Potential design levers include:

• Oval or capsule-shaped geometry.
• Lower tablet height.
• Low-friction film coating.
• Reduced edge chipping.
• High-contrast debossing.
• Unit-dose blister packaging.

The patent position for a conventional caplet is weak unless the geometry, coating or manufacturing process provides a specific and demonstrated technical benefit.

Chewable and orally disintegrating formats

A chewable or orally disintegrating naproxen sodium product could address consumers who have difficulty swallowing tablets. The formulation challenge is substantial because naproxen sodium can have an unpleasant taste and high drug loading. Taste masking may require polymer coatings, ion-exchange resins, lipid barriers, sweetener systems or multiparticulate technology.

An orally disintegrating product must control:

• Taste and mouthfeel.
• Dose uniformity.
• Moisture uptake.
• Mechanical fragility.
• Rapid dispersion.
• Packaging protection.

This format may offer stronger differentiation than a standard tablet, but it also has higher development and packaging costs.

Liquid and powder formulations

Liquid naproxen sodium products may target pediatric, geriatric or dysphagic populations, although OTC pediatric positioning must comply with labeling and safety requirements. A liquid product requires control of solubility, pH, precipitation, viscosity, preservative effectiveness and dose-measurement accuracy.

Powder-in-sachet products can reduce bottle stability burdens and create a portable headache product. Suitable excipient systems may include sweeteners, flavors, flow aids and moisture barriers. The main commercial issue is whether consumers accept reconstitution or direct-to-mouth powder use.

What formulations are protected by naproxen sodium patents?

The original naproxen and naproxen sodium patent estate is long expired in the United States and other major markets. Standard naproxen sodium tablets therefore do not have meaningful active-ingredient patent protection.

Potentially protectable subject matter includes:

• Novel rapid-release matrices.
• Taste-masked particles.
• Orally disintegrating systems.
• Stable liquid compositions.
• Coated multiparticulates.
• Naproxen sodium combinations with caffeine or other active ingredients.
• Abuse-deterrent or modified-release systems.
• Manufacturing processes that reduce impurities or improve content uniformity.
• Packaging systems that prevent moisture-driven degradation.

A formulation patent requires more than substituting one conventional excipient for another. The applicant would need to establish novelty, non-obviousness and a credible technical effect. Comparative dissolution, stability, sensory, manufacturability or bioavailability data are important for a defensible filing.

How strong is the patent estate for naproxen sodium headache products?

Patent category	Current commercial relevance	Strength assessment
Active ingredient	Low	Original exclusivity expired
Conventional 220 mg tablet	Low	Vulnerable to generic and private-label competition
Film coating	Low to moderate	Usually weak unless technically distinctive
Fast-disintegrating formulation	Moderate	Depends on data and claim scope
Taste-masked formulation	Moderate to high	Stronger if sensory and stability benefits are demonstrated
Liquid formulation	Moderate	Potential value in stability and preservation claims
Combination product	Moderate to high	Depends on active ingredients and regulatory pathway
Manufacturing process	Moderate	Often protected through trade secrets and process patents
Packaging and adherence system	Low to moderate	Commercially useful, limited blocking power

The commercial barrier is usually execution rather than patent exclusion. A technically improved formulation can be copied after launch unless the sponsor secures enforceable claims, trade-secret protection, supplier control or a differentiated brand position.

When does naproxen sodium lose exclusivity?

Naproxen sodium has already lost core pharmaceutical exclusivity. The active ingredient is available through generic manufacturers, OTC private-label companies and branded products such as Aleve.

The relevant U.S. regulatory framework is the OTC monograph system for internal analgesic, antipyretic and antirheumatic products. FDA’s final monograph framework permits compliant products to enter without a product-specific new drug application, subject to applicable requirements under 21 CFR Part 343 and current FDA rules.[2]

There is no meaningful remaining small-molecule exclusivity period comparable to a newly approved prescription medicine. A new formulation or combination may create a separate approval and exclusivity position, but that protection would attach to the new product and its claims, not to naproxen sodium itself.

What is the Orange Book status of naproxen sodium headache products?

The Orange Book primarily lists approved drug products submitted through FDA approval applications, including relevant patents and exclusivity information. OTC monograph products may not have the same Orange Book profile as prescription NDA products.

For a standard OTC naproxen sodium product:

• Core naproxen sodium exclusivity is expired.
• A routine monograph-compliant product is not expected to rely on active ingredient patent protection.
• Formulation-specific patents may be listed only if the product is supported by an applicable FDA approval pathway and the patent meets listing requirements.
• Brand and private-label products may have separate NDC listings without creating market exclusivity.

Product-specific Orange Book conclusions require review of the exact sponsor, NDC, approval pathway and listed patents.

Are there Paragraph IV challenges involving naproxen sodium?

Paragraph IV litigation is generally associated with abbreviated new drug applications challenging patents listed for an approved reference product. Standard OTC monograph naproxen sodium tablets do not present the same patent-challenge profile as a protected prescription NDA.

The practical market position is:

Issue	Naproxen sodium OTC market
Paragraph IV risk to original active ingredient	Minimal
Generic substitution risk	High
Private-label entry risk	High
Formulation-patent risk	Product-specific
Barrier from FDA approval	Low for monograph-compliant products
Need for differentiated technology	Commercial rather than mandatory regulatory

A sponsor developing a novel naproxen sodium formulation should expect potential patent scrutiny if its product claims depend on a narrow formulation or combination patent. A conventional tablet has limited ability to deter competitive entry.

What patent litigation and settlement agreements affect naproxen sodium?

There is no widely recognized active U.S. patent dispute that blocks ordinary OTC naproxen sodium 220 mg tablets as a category. Historical disputes involving naproxen products do not restore exclusivity to the active ingredient.

Settlement agreements may arise around later-developed combination products, branded formulations or manufacturing patents. Those agreements are not relevant to ordinary naproxen sodium monotherapy unless they contain product-specific restrictions. A diligence review should separate:

1. Expired compound patents.
2. Expired formulation patents.
3. Active patents covering a specific branded product.
4. Process patents.
5. Trademark and trade-dress rights.
6. Contractual supply or licensing restrictions.

Trademark protection for a brand such as Aleve is commercially more relevant than expired compound patents. It does not prevent sale of generic naproxen sodium under another name.

Which companies compete in naproxen sodium headache pain?

Competition is fragmented across branded OTC products, national retailers, pharmacy chains, mass merchants and generic manufacturers.

Competitive groups

• Branded OTC products, including Bayer’s Aleve franchise.
• Retailer private-label products.
• Generic manufacturers supplying pharmacies and distributors.
• Contract manufacturers producing tablets, caplets and packaged OTC products.
• Combination-product developers targeting migraine and headache consumers.

The most defensible commercial positions are likely to come from brand recognition, retail distribution, dosage-form convenience, packaging, price architecture and a clear consumer benefit. A standard 220 mg tablet has limited differentiation.

What commercial opportunities exist for naproxen sodium excipients?

Private-label and retailer products

Private-label naproxen sodium is the lowest-risk opportunity from an regulatory and technical perspective. Manufacturers can compete through:

• Lower tablet cost.
• Efficient high-speed compression.
• Simplified coating systems.
• Optimized blister or bottle packaging.
• Retailer-specific pack sizes.
• Dual-language or accessibility-focused labeling.
• Stable supply of active ingredient and excipients.

Margin depends heavily on procurement, line utilization, packaging automation and retailer contracts.

Premium fast-onset positioning

A rapid-dissolution formulation can support premium positioning if the sponsor can substantiate a meaningful performance difference. The claim should be based on dissolution and, where appropriate, clinical or pharmacokinetic evidence. Faster in-vitro dissolution alone may not establish faster clinical headache relief.

Headache and migraine combination products

A combination with caffeine could target consumers seeking a headache-specific product. The development burden increases because the sponsor must assess total active-ingredient labeling, interaction risks, dose limits, consumer warnings and applicable FDA requirements.

A combination product can create stronger intellectual-property potential than naproxen sodium alone, particularly if the formulation controls release, reduces irritation or improves stability. It also creates greater regulatory and safety exposure.

Senior and dysphagia-focused formats

Easy-swallow caplets, smaller tablets, orally disintegrating tablets and unit-dose powders can address adherence barriers. The strongest opportunity is likely a dosage form that offers measurable convenience without introducing a large manufacturing cost increase.

Manufacturing and supply-chain opportunities

Excipient selection can reduce cost and improve resilience through:

• Direct compression instead of wet granulation.
• Fewer raw-material vendors.
• Excipient standardization across multiple OTC products.
• Lower coating weight.
• Reduced tooling wear.
• Moisture-resistant packaging only where justified by stability data.
• Dual sourcing for high-risk excipients.

These advantages are often protected more effectively as trade secrets than as patents.

How does naproxen sodium compare with ibuprofen for headache pain?

Factor	Naproxen sodium	Ibuprofen
Common OTC dose	220 mg	200 mg
Typical dosing interval	8 to 12 hours	4 to 6 hours
Salt form	Sodium naproxen	Usually ibuprofen acid or tablet-specific formulation
Market position	Longer-duration OTC analgesia	High-volume general pain and fever relief
Tablet differentiation	Fast-disintegrating, caplet, liquid and combination options	Broad dosage-form and combination competition
Patent position	Core exclusivity expired	Core exclusivity expired
Commercial risk	Lower-frequency dosing but NSAID warnings	High competition and frequent dosing
Excipient opportunity	Dissolution, swallowability, taste masking	Similar, with broader pediatric and liquid competition

Naproxen sodium can support longer dosing intervals than ibuprofen under labeled directions, while ibuprofen has stronger market breadth across pediatric, liquid and combination products. Neither active ingredient has a durable composition-of-matter barrier.

What generic launch risks exist for a new naproxen sodium product?

A new product faces five main risks:

1. Price compression. Standard 220 mg tablets are easy to source and difficult to differentiate.
2. Retail substitution. Pharmacies and retailers can substitute lower-priced private-label products.
3. Limited patent blocking power. Conventional excipient changes rarely prevent competition.
4. Claim scrutiny. “Fast acting” or “long lasting” claims require support and must align with FDA labeling rules.
5. Safety communication. NSAID cardiovascular and gastrointestinal warnings limit aggressive consumer positioning.

The best launch scenario is a differentiated dosage form supported by measurable performance data, a protected or difficult-to-copy manufacturing process, and distribution through a channel that values convenience over lowest unit cost.

What FDA regulatory status applies to naproxen sodium headache products?

Naproxen sodium OTC products are regulated as internal analgesic products. FDA labeling and conditions of use must comply with the applicable OTC framework, including active ingredient, strength, directions, warnings and dosing restrictions.[1,2]

A sponsor developing a conventional monograph-compliant product generally has a shorter regulatory path than a sponsor developing:

• A new combination.
• A pediatric dosage form.
• A modified-release product.
• A novel liquid system.
• A therapeutic claim outside the established OTC labeling framework.
• A product requiring an NDA or other application-based pathway.

Inactive ingredients must be suitable for the route and dosage form, comply with applicable quality standards and be supported by appropriate manufacturing and stability controls. FDA’s Inactive Ingredient Database is a useful reference for precedent, but prior use does not replace product-specific quality assessment.[3]

Key Takeaways

• Naproxen sodium 220 mg is a mature OTC NSAID for temporary relief of headache and other minor aches and pains.
• Core active-ingredient exclusivity has expired, making ordinary tablets vulnerable to generic and private-label competition.
• The most practical excipient opportunities are rapid disintegration, smooth film coating, taste masking, liquid stability and orally disintegrating formats.
• Conventional excipient substitutions have weak patent value unless supported by unexpected technical results.
• Combination products, taste-masked systems and novel delivery formats offer stronger intellectual-property potential.
• Trade secrets, supplier control, manufacturing efficiency and retail distribution may provide more commercial protection than a narrow formulation patent.
• No biosimilar risk applies because naproxen sodium is a small-molecule drug, not a biologic.
• Product-specific Orange Book, litigation and Paragraph IV conclusions depend on the exact sponsor, NDC, approval pathway and formulation.

FAQs

Does naproxen sodium require a special excipient to work faster for headache?

No. The sodium salt already supports dissolution compared with naproxen acid. Excipients can improve tablet breakup and wetting, but faster dissolution does not automatically establish faster clinical relief.

Can a company patent a naproxen sodium tablet using croscarmellose sodium?

Possibly, but the excipient name alone is unlikely to support a strong patent. Protection would require a novel formulation and evidence of an unexpected technical advantage, such as improved dissolution, stability or manufacturability.

Is naproxen sodium a biosimilar product?

No. Naproxen sodium is a chemically synthesized small molecule. The relevant competitive products are generics, OTC monograph products, private-label products and branded alternatives.

Can naproxen sodium be sold as a migraine treatment?

A sponsor must distinguish general headache or minor-pain labeling from migraine-specific claims. A migraine claim may require a different regulatory and clinical strategy than a standard OTC monograph product.

Which packaging is best for naproxen sodium tablets?

Bottles generally minimize cost, while blister packs improve unit-dose portability, moisture control and adherence. The appropriate choice depends on stability data, retailer requirements, target consumer and packaging economics.

References

1. U.S. Food and Drug Administration. (2023). OTC monograph M013: Internal analgesic, antipyretic, and antirheumatic drug products.
2. U.S. Food and Drug Administration. (2024). Code of Federal Regulations, Title 21, Part 343: Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use.
3. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database.
4. U.S. National Library of Medicine. (2024). DailyMed: Naproxen sodium drug labels.
5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Washington, DC: FDA.